CFTR Modulator Therapy For N1303K Mutations

被引：0
|
作者：
Barletta, P. [1 ]
Ortiz, M. G. Tupayachi [1 ]
Baumlin, N. [2 ]
Salathe, M. A. [2 ]
机构：
[1] Univ Miami Hosp, Pulm & Crit Care, Miami, FL USA
[2] Univ Kansas, Med Ctr, Internal Med, Kansas City, KS 66103 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4321
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical and functional efficacy of elexacaf tor/tezacaf tor/ivacaf tor in people with cystic fibrosis carrying the N1303K mutation
    Sadras, Ido
    Kerem, Eitan
    Livnat, Galit
    Sarouk, Ifat
    Breuer, Oded
    Reiter, Joel
    Gileles-Hillel, Alex
    Inbar, Ori
    Cohen, Michael
    Gamliel, Ayelet
    Stanleigh, Noemie
    Gunawardena, Tarini
    Bartlett, Claire
    Gonska, Tanja
    Moraes, Theo
    Eckford, Paul D. W.
    Bear, Christine E.
    Ratjen, Felix
    Kerem, Batsheva
    Wilschanski, Michael
    Shteinberg, Michal
    Cohen-Cymberknoh, Malena
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (06) : 1062 - 1069
  • [32] CFTR Modulator Therapy for Cystic Fibrosis
    Grasemann, Hartmut
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (21): : 2085 - 2088
  • [33] Generation of an induced pluripotent stem cell line (MHHi018-A) from a patient with Cystic Fibrosis carrying p.Asn1303Lys (N1303K) mutation
    Merkert, Sylvia
    Schubert, Madline
    Haase, Alexandra
    Janssens, Hettie M.
    Scholte, Bob
    Lachmann, Nico
    Goehring, Gudrun
    Martin, Ulrich
    STEM CELL RESEARCH, 2020, 44
  • [34] SIMULTANEOUS DETECTION OF DELTA-F508, G542X, N1303K AND 1717-1G-]A MUTATIONS IN CYSTIC-FIBROSIS BY CAPILLARY ELECTROPHORESIS IN POLYMER NETWORKS
    GELFI, C
    RIGHETTI, PG
    MAGNANI, C
    CREMONESI, L
    FERRARI, M
    CLINICA CHIMICA ACTA, 1994, 229 (1-2) : 181 - 189
  • [35] Triple CFTR Modulator Therapy for Cystic Fibrosis
    Holguin, Fernando
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (17): : 1671 - +
  • [36] Chronic rhinosinusitis in the era of CFTR modulator therapy
    Stone, Roy Gavin
    Short, Christopher
    Davies, Jane C.
    McNally, Paul
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (02) : 208 - 213
  • [37] Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations
    Harutyunyan, Misak
    Huang, Yunjie
    Mun, Kyu-Shik
    Yang, Fanmuyi
    Arora, Kavisha
    Naren, Anjaparavanda P.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2018, 314 (04) : 1529 - 1543
  • [38] Regulatory interactions of N1303K-CFTR and ENaC in Xenopus oocytes:: evidence that chloride transport is not necessary for inhibition of ENaC
    Suaud, Laurence
    Yan, Wusheng
    Carattino, Marcelo D.
    Robay, Amal
    Kleyman, Thomas R.
    Rubenstein, Ronald C.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2007, 292 (04): : C1553 - C1561
  • [39] Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence
    Huang, Yunjie
    Paul, Grace
    Lee, Jesun
    Mccoy, Karen
    Naren, Anjaparavanda P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (10) : 1231 - 1235
  • [40] Entering the era of highly effective CFTR modulator therapy
    Zemanick, Edith T.
    Accurso, Frank J.
    LANCET, 2019, 394 (10212): : 1886 - 1888
12345